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Rigorous quality control steps, termed checkpoints, tightly regulate progression through the cell cycle. DNA-damaging chemotherapy
and radiation activate functional cellular checkpoints. These checkpoints can facilitate DNA repair and promote cell death in
unrepaired cells. There are at least three DNA damage checkpoints – at G1/S, S, and G2/M – as well as a mitotic spindle checkpoint.
Most cancer cells harbour mutations in tumour suppressors and/or oncogenes, which impair certain cell checkpoints. Inhibiting the
remaining cell checkpoints – particularly after exposure of cancer cells to chemotherapy and/or radiation – allows cell death, a
strategy now being employed in cancer therapeutics. With our increasing knowledge of cell cycle regulation, many compounds have
been developed to inhibit specific checkpoint components, particularly at the G2/M transition. One such target is checkpoint kinase-1
(Chk1). We review here the molecular framework of the cell cycle, the rationale for targeting Chk1, the preclinical concepts related
to the development of Chk1 inhibitors, and the efficacy and safety results from Chk1 inhibitors now in phase I/II trials.
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The cell cycle is organised into a series of dependent pathways,
whereby the initiation of each event is dependent upon successful
completion of previous events. In this way, replicating cells
traverse the four distinct phases of the cell cycle consecutively: G1
followed by S, followed by G2 and, finally, M. This ordered
progression is guarded by checkpoints capable of delaying the cell
cycle in response to intra- or extracellular stressors. As part of the
cell cycle surveillance system, the DNA damage and spindle
checkpoints protect the cell from genomic instability. Checkpoints
are important quality control measures that ensure the proper
sequence of cell cycle events and allow cells to respond to DNA
damage.
Increasingly, checkpoint inhibition has become an area of novel
drug development. In the setting of DNA damage, checkpoint
inhibition leads to genomic instability, and subsequent cell death.
The first checkpoint, found at the G1/S transition, is compromised
in many malignant cells, due to mutations in various tumour
suppressor genes, including retinoblastoma protein (Rb) and p53.
Cells deficient in the G1 checkpoint are dependent on the S and G2
checkpoints for DNA repair. Checkpoint kinase-1 (Chk1) is an
active transducer kinase at both the S and G2 checkpoints,
rendering it a target for rational anticancer drug development. In
the presence of DNA damage, Chk1 inactivation abrogates G2
arrest, resulting in preferential cancer cell death (Chen et al, 2003).
This article serves to review the (1) current molecular pathways
comprising the cell cycle checkpoint machinery, (2) inhibition of
Chk1 as an effective means of abrogating G2 arrest, and (3) current
Chk1 inhibitors in use in phase I clinical trials.
MOLECULAR COMPONENTS OF THE DNA
DAMAGE CHECKPOINTS
Components of the checkpoint mechanism include sensors,
mediators, transducers, and effectors, which work cooperatively
in different phases of the cell cycle (Sancar et al, 2004) (Figure 1).
The phosphatidylinositol 3-kinase-related kinases ATM (ataxia–
telangiectasia mutated) and ATR (ATM and Rad3-related) are
transducers that coordinate the initiation, amplification, and
activation of the checkpoint through phosphorylation of many
different targets. Although ATM and ATR are classified as
transducers, they are capable of recognising DNA damage.
Ataxia–telangiectasia mutated is activated by DNA damage from
ionising radiation, whereas ATR is activated by DNA damage and
DNA replication stress. In the case of ATM, DNA double-strand
breaks (DSBs) induce ATM homodimer dissociation. The resultant
ATM monomers are recruited to sites of DSBs, with the aid of the
putative sensor MRN complex, comprised of Mre11, Rad50, and
Nbs1 (Van Den Bosch et al, 2003). In the case of ATR, short
sequences of single-strand breaks are generated from DSBs, and
coated with replication protein A (RPA). Replication protein
A-coated DNA recruits ATR together with its interacting protein
ATRIP (Zou and Elledge, 2003). Full activation of the ATR/ATRIP
complex and successful checkpoint function requires loading of
the sensor Rad17 and 9-1-1 (Rad9, Rad1, and Hus1) complexes
onto DNA (Zou et al, 2002).
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ATR substrates. In one model, ATM phosphorylates histone
H2AX, flanking the sites of DNA damage. Proteins including
mediator of DNA damage checkpoint 1 (MDC1), p53-binding
protein (53BP1), and BRCA1 accumulate at phosphorylated H2AX
(gH2AX), culminating in Chk2 activation (Canman, 2003). In
another model, ATR interacts with the mediator TopBP1 to
phosphorylate a number of proteins, including H2AX (Liu et al,
2006). The interaction of ATR with TopBP1, and its downstream
mediator claspin, results in recruitment and phosphorylation of
BRCA1 and subsequent activation of Chk1.
Checkpoint kinase-1 and Chk2 are the checkpoint transducer
kinases that function downstream in the DNA-damage checkpoint
signalling pathway. Although structurally dissimilar, Chk1 and
Chk2 are serine/threonine kinases that serve as functional
analogues (Bartek et al, 2001). Checkpoint kinase-2, expressed
throughout the cell cycle, is activated in the presence of DNA
damage (Lukas et al, 2001). In contrast, Chk1, preferentially
expressed during S and G2, has constitutive activity that is
amplified in the presence of DNA damage (Zhao et al, 2002).
Ataxia–telangiectasia mutated phosphorylates Chk2 at threonine
68, and ATR phosphorylates Chk1 at serines 317 and 345.
Significant crosstalk exists between the ATM/Chk2 and ATR/
Chk1 pathways (Gatei et al, 2003). Although Chk1 and Chk2 have
overlapping roles in checkpoint signalling, only Chk1 is indis-
pensable for mammalian survival (Liu et al, 2000).
Another transducer kinase, downstream from the stress–
response p38 MAPK pathway and named MAPKAP kinase-2
(MK2), is directly involved in phosphorylating effectors CDC25B
and C, and in maintaining G1, S, and G2 checkpoints triggered by
UV-induced DNA damage (Manke et al, 2005). MAPKAP kinase-2
is activated by cisplatin, camptothecin, and doxorubicin, and the
MK2 response is essential for the survival of p53-deficient cells
following exposure to these agents (Reinhardt et al, 2007).
Together, the proximal transducers ATM and ATR and the distal
transducers Chk1, Chk2, and MK2 phosphorylate a variety of
effector molecules, such as p53 and CDC25 phosphatases,
culminating in cell cycle arrest. For the purpose of this review,
an understanding of CDC25 phosphatases is key. The three CDC25
isoforms – A, B, and C – are active in different phases of the cell
cycle. CDC25 phosphatases remove inhibitory phosphate groups
from cyclin/cyclin-dependent kinase (CDK) complexes, promoting
cell cycle progression. In response to DNA damage, the checkpoint
kinases phosphorylate CDC25 phosphatases, resulting in CDC25
inactivation through either ubiquitin-mediated degradation or
cytoplasmic sequestration. In this manner, the checkpoint kinases
serve as negative regulators of the CDC25 phosphatases.
CELL CYCLE CHECKPOINTS
Although there is redundancy in checkpoint signalling, the relative
contribution of individual checkpoint transducers and effectors
varies during the course of the cell cycle, as described below.
G1 checkpoint
The G1 checkpoint is the first defence against genomic stress in
cycling cells. In response to DNA damage, the G1 checkpoint
prevents cells from entering the S phase by inhibiting the initiation
of DNA replication. At this checkpoint, Chk2 is activated by
ATM to phosphorylate CDC25A phosphatase (Massague, 2004),
preventing activation of cyclin E(A)/CDK2 (Mailand et al, 2000)
and temporarily halting the cell cycle. It has been proposed that G1
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Figure 1 Cell cycle checkpoint pathways. Once DNA damage is identified with the aid of sensors, the checkpoint transducers ATM and ATR undergo
conformational change and/or localisation, resulting in their activation. Together with their mediators, ATM and ATR activate a series of downstream
molecules, including the checkpoint transducer kinases. Checkpoint kinase-2 and Chk1 inactivate CDC25 phosphatases, culminating in cell cycle arrest.
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murine double minute protein and p53, resulting in p53
stabilisation (Takai et al, 2002) and accumulation. p53 activates
transcription of the CDK inhibitor p21, which in turn inhibits
cyclin E(A)/CDK2 (Harper et al, 1993) and preserves the
association of Rb with E2F. Reports that Chk2-null mouse embryo
fibroblasts manifest p21 induction and G1 arrest upon exposure to
radiation have called into question the role of Chk2 in DNA
damage-induced G1 arrest (Jack et al, 2002). Instead, Chk2 appears
to be necessary for p53-mediated apoptosis (Jack et al, 2002).
While interactions between Chk2 and p53 are under investigation,
most human cancers are deficient in p53 (Kastan et al, 1991). As a
result, cancer cells accelerate through the cell cycle until they meet
the remaining barriers of the cell cycle, namely, the S and G2
checkpoints.
S-phase checkpoint
The S-phase checkpoint serves to address both DNA replication
errors and DNA damage incurred during S phase (Bartek et al, 2004).
Ionising radiation may transiently slow DNA synthesis through
two parallel pathways: ATR(ATM)/Chk1(Chk2)/CDC25A/CDK2 and
ATM/NBS1/MRE11/structural maintenance of chromosome 1
(SMC1) (Falck et al, 2002). In the first pathway, DNA damage
invokes ATR/Chk1 and ATM/Chk2, resulting in CDC25A degrada-
tion, thereby inhibiting cyclin E(A)/CDK2 (Bartek et al, 2004) and
progression through S phase. Checkpoint kinase-1 is thought to be
the primary S-phase checkpoint kinase, with Chk2 playing a
supportive role. This is supported by studies with siRNAs targeting
Chk1 and Chk2, demonstrating that downregulation of Chk1, but not
Chk2, abrogates camptothecin- or 5-fluorouracil-induced S-phase
arrest (Xiao et al, 2003). In the second pathway, the sensor MRN
complex recruits ATM to sites of DNA damage with the help of the
MDC1 (Watrin and Peters, 2006). Once localised to damaged DNA,
ATM phosphorylates SMC1, a component of the cohesin complex
thought to function in DNA repair. The mechanism by which SMC1
slows S-phase progression is under study.
G2 checkpoint
Cells that have either incurred DNA damage in G2 phase, or that
have escaped the G1 and S checkpoints despite earlier genomic
insults, are stalled at the G2 checkpoint. At G2, Chk1 is activated
by ATR to phosphorylate CDC25A, -B, and -C (Boutros, 2006),
preventing cyclin B/CDK1 activation and resulting in G2 arrest.
Another mechanism of G2 arrest is provided by stress-induced
activation of p38 MAPK/MK2 and subsequent inactivation of
CDC25B/C, as described earlier (Manke et al, 2005; Reinhardt et al,
2007). By inducing the transcription of p21 and other proteins, p53
also plays a role in the G2 checkpoint (Taylor and Stark, 2001).
G2 ABROGATION AS AN ANTICANCER STRATEGY
Cancer cells are dependent on the S and G2 checkpoints for repair
of DNA damage, due to the presence of defective G1 checkpoint
mechanisms. Because the S-phase checkpoint facilitates slowing,
rather than arrest, of the cell cycle, a cancer cell harbouring DNA
damage may progress through the S checkpoint, only to halt at the
G2 checkpoint. Thus, the G2 checkpoint is a key guardian of the
cancer cell genome, and it has emerged as an attractive therapeutic
target for anticancer therapy. G2 abrogation prevents cancer cells
from repairing DNA damage, forcing them into M phase and the
so-called ‘mitotic catastrophe’ and apoptosis.
The ideal G2 checkpoint abrogator would be selective, targeting
a molecule not involved in G1 checkpoint or S-phase checkpoint
or, if involved, in a nonredundant fashion (Kawabe, 2004).
Candidate targets for G2 abrogation are discussed below.
ATM/ATR inhibition
Ataxia–telangiectasia mutated and ATR activate pathways
involved in cell cycle checkpoints, apoptosis, and DNA repair;
therefore, they are not specific G2 checkpoint abrogators. None-
theless, caffeine, which has many molecular effects, including ATM
and ATR inhibition, has been shown to potentiate the cytotoxicity
of nitrogen mustard by disrupting the G2 checkpoint, inducing
damaged cells to undergo mitosis before properly repairing lesions
in their DNA (Lau and Pardee, 1982). The clinical toxicity of
caffeine at millimolar concentrations prevents further clinical
evaluation (Stewart et al, 1987). A less toxic derivative of caffeine,
pentoxifylline, has been tested in clinical trials; however, its effects
on cell biology are also nonspecific (Kawabe, 2004). More specific
ATM inhibitors are currently in development (Hickson et al, 2004).
Manipulation of CDC25 and WEE1
Another strategy to abrogate the G2 checkpoint is to activate
CDC25C phosphatase, in conjunction with DNA damage. Acti-
vating this phosphatase results in dephosphorylation and
activation of cyclin B/CDK1, causing cell cycle progression to M
phase. To date, no such activators have been developed. An
alternative method of G2 abrogation is the inhibition of WEE1, a
protein that opposes CDC25 activity by phosphorylating and
inactivating cyclin/CDK complexes. As an example, the WEE1
inhibitor PD0166285 has demonstrated G2 checkpoint inhibition
in preclinical models (Hashimoto et al, 2006).
MK2 inhibition
The p38 MAPK/MK2 pathway has been implicated in several
cancer cell pathways, from those related to inflammation, growth,
replication, apoptosis, angiogenesis, and metastasis. More recently,
this pathway has been found to be a regulator of checkpoint
controls, particularly at the G2/M transition (Manke et al, 2005).
MK2-depleted p53-deficient cells cause not only abrogation of the
CDC25A-mediated S-phase checkpoint after cisplatin treatment,
but also loss of the CDC25B-mediated G2/M checkpoint following
doxorubicin (Reinhardt et al, 2007). As such, an MK2 inhibitor
may sensitise cancer cells to cytotoxic agents. However, in one
study of Chk1 and MK2 downregulation with siRNA, suppression
of MK2 did not abrogate chemotherapy-induced cell cycle arrest,
and it appeared to antagonise checkpoint abrogation provided by
suppression of Chk1 (Xiao et al, 2006).
HSP90 inhibition
An indirect and nonspecific method of checkpoint abrogation is
provided by inhibition of the molecular chaperone heat shock
protein-90 (HSP-90). In preclinical studies, the HSP-90 inhibitor
17-AAG has been shown to deplete Chk1, an HSP-90 client
(Arlander et al, 2003). Likewise, G2/M abrogation was seen when
17-AAG was combined with SN38 in p53-deficient cells (Tse et al,
2005) and when combined with irradiation in human lung cancer
cells. The HSP-90 inhibitor 17-AAG is in clinical development,
along with many other HSP-90 inhibitors.
Chk1 inhibition
Perhaps the most relevant approach to G2 checkpoint abrogation
is the inhibition of Chk1 kinase. Checkpoint kinase-1 is a key
element in the DNA damage response pathway and plays a crucial
role in the S-phase checkpoint and G2 checkpoint, largely
mediated by CDC25A. In addition, Chk1 is required for mitotic
spindle checkpoint function (Zachos et al, 2007). The spindle
checkpoint delays anaphase until proper chromosomal attachment
and segregation, and depletion of Chk1 induces chromosomal
G2 checkpoint abrogation
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enhancing the efficacy of DNA-damaging agents that cause S or G2
arrest, but also potentiating antimitotic activity.
Use of DNA-damaging agents or antimitotics, in combination with
a Chk1 inhibitor, not only confers enhanced tumour kill, but also
may eliminate cell cycle-mediated drug resistance. Depending on the
cell’s position in the cell cycle and on the particular checkpoints
activated, a cell may demonstrate a relative insensitivity to a
chemotherapeutic agent (Shah and Schwartz, 2001). Appropriate
scheduling and sequencing of cell cycle checkpoint inhibitors could
thus overcome the limited efficacy of cytotoxic drugs.
Several Chk1 inhibitors have been studied in the laboratory over
the past decade, some of which have been reviewed previously
(Kawabe, 2004; Tse et al, 2007a). Examples of compounds that are
in advanced preclinical and/or early clinical development are listed
in Table 1, and potential biomarkers of Chk1 inhibition are
presented in Table 2.
CHK1 INHIBITORS IN THE CLINIC
UCN-01
7-Hydroxystaurosporine (UCN-01) has multiple cell cycle effects
including inhibition of Chk1 and MK2 with IC50 values of 7nM
(Kawabe, 2004) and 95nM (Reinhardt et al, 2007), respectively. The
compound UCN-01 has demonstrated in vitro synergy with many
chemotherapeutic agents, leading to multiple clinical trials
employing UCN-01 in combination (Tse et al, 2007a). The clinical
utility of UCN-01 may be limited by its avid plasma-
protein binding and dose-limiting hyperglycaemia (Kortmansky
et al, 2005).
CBP501
CBP501 is a synthetic peptide that was generated to suppress
phosphorylation of CDC25C at serine 216, to prevent cytoplasmic
sequestration. Subsequently, the inhibitory effects of CBP501 were
found to be most pronounced against MK2 (IC50 0.9mM), C-Tak1
(IC50 1.4mM), and Chk1 (IC50 3.4mM) (Sha et al, 2007). In vitro and
in vivo, CBP501 increased the anticancer activity of cisplatin
and bleomycin. In a single-agent phase I clinical trial, patients
received doses of 0.9–7.2mgm
 2 i.v. weekly for 3 weeks with 1
week off. Preliminary results indicate the main toxicity to be grade
2 allergic reaction, with no dose-limiting toxicity reported to date.
Decreased phosphorylation of CDC25C at serine 216 was demon-
strated in peripheral blood lymphocytes from 7 of 12 patients
evaluated, suggesting biologic activity at the G2 checkpoint
(Gordon et al, 2006). A combination phase I study of CBP501
and cisplatin is currently underway.
XL844
XL844 (EXEL9844) is a novel and specific inhibitor of both Chk1
and Chk2, with IC50 values of 2.2 and 0.2nM, respectively
(Matthews, 2006). In preclinical studies, it reversibly and
competitively inhibited Chk1 at the ATP-binding site. In an
in vitro CML model, XL844 abrogated the G2 checkpoint activated
by daunorubicin-induced DNA damage, as indicated by CDK1
activation and an increase in phosphohistone H3 (a marker of
mitotic entry). In a CML nude mice survival model, the
combination of XL844 and daunorubicin caused a significant
increase in median survival time. In a panel of multiple solid
tumour cell lines, XL844 had little effect as a single agent, but
substantially increased the cytotoxicity of gemcitabine (Matthews
et al, 2007). XL844 was shown to affect both the S and G2
checkpoints by blocking gemcitabine-induced DSBs and CDC25A
phosphorylation, inducing premature mitotic entry. XL844 also
resulted in an increase in gemcitabine-induced gH2AX. In a
pancreatic tumour xenograft model, increasing doses of XL844
enhanced gemcitabine’s antitumour activity, without an increase
in toxicity. XL844 was the first specific Chk1/2 inhibitor to enter
Table 1 Examples of Chk1 inhibitors
Compound Chemistry Manufacturer
In vitro
Chk1
IC50 (in nM)
Other
targets
(IC50 in nM)
Phase of
development References
UCN-01 Staurosporine derivative Kyowa (Tokyo, Japan) 7 PKC (4.1),
MK2 (95)
Phase I/II See text
Series of compounds Tricyclic pyrazoles Abbott (Abbott Park, IL, USA) 0.4–24 Preclinical Tao et al (2007a)
Series of compounds Macrocyclic ureas Abbott 3–15 Preclinical Tao et al (2007b)
Series of compounds Granulatimide analogues Laboratoire SEESIB (Aubiere, France) 27–33 Preclinical Conchon et al (2007)
CHIR-124 Benzimidazole quinolinone Chiron (Emeryville, CA, USA) 0.3 Chk2 (9) Preclinical Tse et al (2007b)
CBP501 Peptide CanBas (Numazu, Japan) 3400 MK2 (900),
cTak1 (1400)
Phase I Gordon et al (2006);
Sha et al (2007)
XL844 Undisclosed Exelixis (South San Francisco, CA, USA) 22 Chk2 (0.2) Phase I Matthews (2006);
Matthews et al (2007)
PF-00477736 Diazapinoindolone Pfizer (La Jolla, CA, USA) (Ki 0.49)
(EC50 45)
Chk2 (Ki 47),
CDK1 (Ki 9900)
Phase I Anderes et al (2006);
Hallin et al (2007)
AZD7762 Undisclosed AstraZeneca (Waltham, MA, USA) 5 Chk2 (o10) Phase I Ashwell (2007)
CDK1¼cyclin-dependent kinase-1; Chk1¼checkpoint kinase-1; Chk2¼checkpoint kinase-2; MK2¼MAPKAP kinase-2; UCN-01¼7-hydroxystaurosporine.
Table 2 Potential biomarkers of Chk1 inhibition
Biomarker Rationale
Expected
outcome
a
Chk1 phosphoserine 296 Chk1
autophosphorylation site
k
Chk1 phosphoserine 345 Chk1 activation site m or k, depending
on properties of
specific inhibitor
gH2AX Activated at sites of
DNA damage
m
Phosphohistone H3 Marker of mitotic entry m
CDC25C phosphoserine 216 Negative regulation of
CDC25C phosphatase,
causing G2 arrest
k
Chk1¼checkpoint kinase-1.
aExpected outcome with addition of Chk1 inhibitor to
chemotherapy-treated cells.
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lymphocytic leukaemia; however, this trial closed due to slow
enrollment. Currently, a phase I dose-escalation study of XL844
alone and in combination with gemcitabine is underway.
PF-00477736
PF-00477736 is a potent, selective ATP-competitive diazapinoin-
dolone that inhibits Chk1 with a Ki of 0.49nM. (Anderes et al,
2006). The ability of PF-00477736 to abrogate the G2 checkpoint
in camptothecin-treated cells was demonstrated by an increase
in phosphohistone H3 levels and by an increase in a sub-G1
population. PF-00477736 also induced checkpoint abrogation in
gemcitabine-treated cells, as demonstrated by a number of
molecular endpoints, including decreased activation of Chk1 at
serine 345, increased gH2AX, and increased apoptosis. PF-
00477726 enhanced the cytotoxicity of gemcitabine, irinotecan,
and carboplatin, with selectivity for p53-defective cancer cell lines
compared with p53-competent cells. In colon cancer xenograft
models, PF-00477736 enhanced the activity of gemcitabine and
irinotecan. On the basis of these and other studies, PF-00477736 is
currently being evaluated in a phase I clinical trial in combination
with gemcitabine.
PF-00477736 has also been shown to enhance the antitumour
activity of docetaxel, an antimicrotubule agent, indicating a role
for Chk1 in the mitotic spindle checkpoint (Hallin et al, 2007).
In vitro, PF-00477736 abrogated docetaxel-induced G2/mitotic
arrest, resulting in a more effective induction of apoptosis than
produced by docetaxel alone. PF-00477736 also significantly
potentiated the activity of docetaxel in Colo205 xenografts by
enhancing tumour regression and prolonging survival, without
added systemic toxicity. Treatment with PF-00477736 also
modulated spindle checkpoint downstream effectors cyclin B,
securin, BubR1, and Aurora.
AZD7762
Another potent and selective Chk1 inhibitor that abrogates the G2
checkpoint, AZD7762, has been shown to inhibit Chk1 at an IC50
of 5nM in an HT29 cell-based assay (Ashwell, 2007). In vitro,
treatment with AZD7762 resulted in a reduction in the concentra-
tion of DNA-damaging agents required to inhibit tumour cell
growth by 50 and 100% (i.e., reduction in GI50 and GI100 values).
The effects of AZD7762 were more pronounced in p53 mutant cell
lines. In H460 mouse xenograft models, AZD7762 potentiated
both the efficacy of gemcitabine and irinotecan, causing tumour
growth delays of 410-fold and 43-fold, respectively. Investiga-
tors confirmed checkpoint pathway modulation by evaluating
surrogate markers in tumour tissue treated with AZD7762,
demonstrating decreased autophosphorylation of Chk1 at serine
296, and increased gH2AX. In contrast to PF-00477736, AZD7762
produced increased phosphorylation of Chk1 at serine 345. A
combination phase I study of AZD7762 and irinotecan is currently
underway.
CONCLUSION
Recognising that cancer cells are more dependent on the G2
checkpoint for DNA damage repair than normal cells,
G2 checkpoint abrogation is being investigated as a means of
enhancing the therapeutic index of cytotoxic agents. Although at
least two phase I trials were performed using Chk1 inhibitors as
single agents, preclinical evidence suggests that G2 checkpoint
abrogation will be most successful when Chk1 inhibitors are used
in combination with chemotherapy or radiation therapy. In vitro,
Chk1 inhibitors increase the anticancer activity of chemotherapy,
demonstrating the potential to sensitise resistant cells. In limited
xenograft models, this enhanced anticancer activity is not
associated with increased toxicity. The results of ongoing clinical
trials will determine whether G2 checkpoint abrogation changes
the risks and benefits of chemotherapy.
While this review focuses on Chk1 inhibitors that promote cell
cycle progression, other investigators are developing specific CDK
inhibitors that inhibit cell cycle progression (Shapiro, 2006).
Although seemingly disparate approaches, each exploits cancer cell
mutations and repair mechanisms to achieve therapeutic benefit. A
common challenge will be determining the proper combination,
and sequence, of targeted cell cycle drugs and cytotoxic therapy.
Efforts have long been underway and, as reviewed here, several
Chk1 inhibitors offer promise.
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